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1. Introduction 
Clinical assessment of outcome for post heart transplant recipients who were bridged with 
ventricular assist device is essential for service evaluation, device evaluation and audit. This 
chapter will provide a summary assessment of clinical studies and reviews. While most of 
the data available is retrospective, important aspects of this assessment relies on the quality 
of assessment and timely re-evaluation of strategy used in the assessment. 
We will review the clinical outcomes measured so far in the field of heart transplant recipients 
who were bridged with VAD. In this chapter we will review the ongoing methods of 
assessment of outcomes for transplant recipients bridged by VAD and discuss the potential 
challenges facing the clinicians. We will finalize with brief conclusions and future directions. 
2. Survival following heart transplantation: Does VAD Type matter? 
There have been many clinical studies comparing outcomes following heart transplantation. 
Only one has been done in a multicenter fashion with clinically relevant as well as a robust 
risk-adjustment.  
In 2006 we asked the question- does survival differ between those who did and did not 
receive the left ventricular assist device (LVAD) following heart transplantation? 
And in summary we found that survival following heart transplantation for patients who 
received an LVAD prior to transplantation was comparable to those who did not receive an 
LVAD. The results of this study were published as lead research article in the British 
Medical Journal earlier this year (Shuhaiber). 
We reviewed all patients above 18 years of age who received heart transplants registered in 
the United Network for Organ Sharing (UNOS) Registry from 1996 to 2004.  The study 
included 2786 status 1/1A/1B heart transplant patients. We used the entry data for all 
patients who received LVAD pulsatile device. Our study design included a prospective 
cohort study in which post-transplant survival between patients who received an LVAD 
and those who did not receive an LVAD was compared.  
Patients were assigned to one of five strata based on the propensity score analysis where the 
first stratum consists of patients most similar to those that had a heart transplant with no 
prior bridging of an LVAD and the last stratum consists of patients most similar to those 
patients that had an LVAD device prior to heart transplantation.  As a sensitivity analysis, a 
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1:1 propensity score matching analysis was also performed. Comparisons of survival 
distributions were made using the Kaplan-Meier method and the risk ratios were estimated 
using Cox proportional model.  
Our primary outcomes as well as risks and exposures included survival following heart 
transplantation in heart transplant recipients who did or did not receive ventricular assist 
device. 
The strength of the study was in adopting a robust statistical methodology that can 
adequately control for confounding variables. A stratified propensity score analysis of data 
revealed that the risk of death following heart transplantation in an LVAD patient was not 
significantly different from those who did not have an LVAD within each stratum (see table 
for estimated hazard ratios and their 95% confidence intervals).  A 1:1 propensity score 
matching analysis also revealed no significant difference in post heart transplant survival 
between the two groups (hazard ratio = 1.18, 95% CIs=0.75 to1.86). 
The propensity score matching was performed in order to control potential selection biases 
that can lead to a false association (or false lack of association) between LVAD and survival. 
Although we attempted to minimize bias through propensity score matching, hidden bias 
could potentially remain because of other relevant known as well as unknown covariates 
not available in the UNOS database. Nonetheless, the work provided an application of 
robust statistical methodology and provided a good signal to noise ratio, that VAD support 
is safe and is not detrimental to outcomes following heart transplantation. 
The other studies published in specialized surgical journals, reflected mainly single center 
experiences. Nonetheless, they supplement the growing interest in the areas of post heart 
transplant outcomes in patients with VAD insertion.  
In a study from Utah (Bull), patients with idiopathic dilated cardiomyopathy (IDC) that had 
placement of a Heart mate I (Thoratec Corp, Pleasanton, Calif) ventricular assist device as a 
bridge to a cardiac transplant were reviewed. The authors studied both alloimmunization as 
well as survival. They found that the VAD group was associated with elevation in 
pretransplantation panel reactive antibody sensitization and a decrease in 1- and 5 year 
survivals after cardiac transplantation. Over the time period from 1993 to 2009, a total of 525 
cardiac transplants were performed. VADs were placed as a bridge to transplant in 110 
patients.  The focus of the study was IDC (n=201) and coronary artery disease (n=213).  The 
authors used variables including gender, age, date of transplant, cause of heart failure, prior 
heart transplant, placement of a ventricular assist device, type of ventricular assist device, 
and panel-reactive antibody sensitization. Analysis was performed by Kaplan-Meier 
survival probabilities and multivariable Cox regression models. 
Interestingly, the authors found that the patients who had idiopathic dilated 
cardiopmyopathy- VAD group had a decreased survival at 1 year (P=0.008) and 5 years (P-
.019) but not at 10 years post transplant. The number of patients was small and it was not 
adjusted according to other important donor variables and use of other life support 
measures such as ventilation or use of intra-aortic balloon pump. The extrapolation to and 
extension of the results to more than 1 year becomes both conceptually and clinically 
difficult to comprehed.  Moreover, the hazard related death is more early at the time of 
transplantation due to re-entry and cardiac injury, or VAD related injury mainly at the 
inflow or outflow conduits.  
In a separate multicenter study of post transplant survival after support with a continuous –
flow left ventricular assist device, the authors followed 468 patients that underwent heart 
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transplantation  (John 2010).  53% underwent cardiac transplant after a median duration of 
LVAD support of 151 days (longest:3.2 years ) of which 23% died, 2.6% recovered 
ventricular function and the device was removed successfully. 21% were still receiving 
LVAD support.  The overall 30-day and 1 year post-transplant survival was 97% and 87%. 
Patients requiring more than 2 units of packed red blood cells in 24 hours during LVAD 
support had a statistically significant inferior 1- year survival than those who did not. 
Implantation of the VAD with its associated risk factors both perioperatively and 
postoperatively is important to appreciate as long as the device is in place. After heart 
transplantation, the device is removed and the patient continues to survive based on the 
context of graft function, immune suppression and overall patient management assuming 
that that no serious transplant-surgery related events occurred. 
A list of contemporary studies reviewing post VAD heart transplant outcomes is detailed in 
table 1. While there are studies that demonstrate superior survival among those who 
received VADs, other studies did not show that.  The single most robust study from our 
group showed that VAD placement really does not have any influence on post-heart 
transplant outcomes. 
Finally, optimal timing of cardiac transplantation after ventricular device implantation is an 
important variable that can directly or indirectly influence outcome. Although intuitively 
the transplantation around the time of VAD placement has been associated with far worse 
outcomes due to patient illness as well as VAD related complications.  In a study based on 
the UNOS registry of 2692 heart transplantations performed between 1999 and 2001, 17% 
received a VAD (Gammie). Almost half of patients with VAD undergoing transplantation 
were upgraded to status 1 A as a result of VAD related complications. Creatinine and total 
bilirubin levels were less in patients undergoing transplantation after 2-4 weeks of 
mechanical support. One-year survival was higher in the non-ventricular assist device than 
in the VAD group. Within the VAD, survival was lowest for patients who received a heart 
within 2 weeks of VAD implantation. Multivariate analysis demonstrated a significant effect 
of time interval from VAD implantation to transplantation on post heart transplantation 
mortality. The plausible explanation underlying this finding is when a patient requires a 
VAD usually they are in decompensated state of heart failure. In this state, there often 
maintain a similar degree of other end-organ injury mainly renal dysfunction. Weeks of 
hemodynamic support are required to achieve normalization of end-organ function and are 
concordant with prior reports that have demonstrated improvement of both hepatic and 
renal function during long-term VAD support (Gammie). Therefore the general rule is to 
wait a few weeks between time of VAD insertion and before heart transplantation.  
3. VAD induced alloimmunization and post heart transplant rejection  
Insertion of VAD is associated with relatively increased risk for blood transfusion. Blood 
contains a large number of antigen load for which the body mounts selective and non-
selective antibodies. These antibodies are naturally formed and can be measured by a test 
called panel reactive assay.  A high PRA has been shown to reduce cardiac graft survival 
because it increases the absolute risk for rejection both in early and late post transplant 
stages. We review contemporary studies regarding the role of alloimmunization and post-
transplant outcomes. 
Also a device such as VAD is placed in circulation, the textured surface of the device results 
in the formation of pseudointima that contains an abundance of T cells, macrophages, and  
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 Author Type LVAD number Median/Mean 
Age 
1 year 
survival 
Post Transplant Survival Bias 
Shuhaiber 
2010 
Thoratec 1354 LVAD 50.6  no 
significant 
difference 
in survival 
between 
the two 
groups 
No difference VAD or no VAD 
John 2010 Heart Mate 
II 
468 54 87% No difference VAD or no VAD 
Bull  2010 Heartmate I 110 54 CAD  
42 IDC 
90 % 
77% 
VAD Bridge to TX inferior survival 
Russo 
2009 
Implantable 
Para-& 
extracorporal 
Intra-1680 
Para-514 
Extra-128 
Intra-50 
Para-46 
Extra-49 
1 year  
Intra-87% 
Para-81% 
Extra-57% 
No difference 
Pal 2009 Authors did 
not specify 
type of 
implantable 
device  
86 49 84% 1 yr 
72% 5 yr 
No difference 
Paltolla 
2009 
Authors did 
not specify 
type of 
implantable  
or 
extracorporal 
device 
1433 
Intracorporeal 
448 
extracorporal 
Intra-50 
Extra-47 
IntraCorp 
85% 1 yr  
70%  5 yr 
 
Extracorp 
 
75% 1 yr 
66% 5 yr 
 
 
Higher with extracorporal 
Klotz 2006 Micromed 
DeBakey,  
50 44 68% No difference 
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monocytes as a result of the continuous dynamic interaction of the blood with the device. 
Aberrant T Cell proliferation and polyclonal B cell hyper-reactivity with CD 40 ligand 
interaction has all been reported in association with the use of the Hearmate I device. The 
interaction between the blood constituents and biomaterials of the VAD, specifically the 
textured chamber surface found in the Heartmate I, may be the responsible for the increased 
immunologic and inflammatory response seen in this group of patients. 
A study from Utah (Drakos 2007), showed that patients with IDC receiving VADs as a 
bridge to transplant were more likely to have a PRA greater than 10% than the precardiac 
transplant population without VADs. In a study by Bull et al, patients who received a VAD 
as a bridge to transplant, the pretransplant PRA was elevated to 35% versus only 5% in the 
patients without VADs. Interestingly, the incidence and severity of acute cellular and 
humoral rejection, immunosuppressive agents, immnosuppression protocols, and cardiac 
allograft vasculopathy did not differ between those with and without VADs in the IDC and 
CAD groups. 
HLA antibodies are present around 3 months following VAD insertion (Kumpati). PRA 
greater than 10% is considered positive for anti-HLA antibodies.  Sensitisation has been 
found to be more prevalent with increasing length of support. Patient factors determine the 
temporal pattern of sensitisation and while some argue that the type of device influences 
allosensitization, others do not (Kumpati). Table 2 reviews the level of sensitization 
following VAD. 
 
Author Type 
LVAD 
number 
Allosensitization 
George 
2008 
Heartmate I 
v.s. 
Heartmate II  
(1999-2006) 
24 
36 
Heartmate II and DeBakey device produced less 
sensitization 
 Heart mate I. There were fewer rejection 
episodes but did not reach  
Statistical significance.   
Drakos 
2007 
Heart Mate I 71 Leuokfilration in 54 patients and fresh frozen 
plasma in 17 patients.  
There were significant trends for less 
sensitization and lower peak PA  
with greater blood transfusion. 
Table 2. Contemporary studies  
The type of VAD as a bridge to transplant does not seem to influence the incidence of 
posttransplant rejection or survival at 1 year post transplant, but can  at 5 years post 
transplant. In addition, the rate and severity of postransplant  rejection has been noted  to be 
higher in LVAD recipients with continous flow devices than in patients with pulsatile 
devices. However, further studies need to be conducted to determine if these observations 
are consistent 
For example, in a recent study by Bull et al, implantation of the Heartmate II device was not 
associated with an increase in the PRA (Bull).  
We also reviewed the UNOS registry from October 1991 and June 1994 to determine the 
influence of the type of left ventricular assisted device as predictor of hospitalizations due to 
rejection following heart transpalntation to delineate any further predictors of such 
outcome. Patients who received a left ventricular assist device (HeartMate [Thoratec Corp., 
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Pleasanton, CA, USA] or Novacor [World Heart Corporation, Ottawa, Canada]) prior to 
heart transplantation were evaluated. Rejection rates between the two devices were 
analyzed using multivariable logistic regression model. We reviewed 1255 patients with 
HeartMate I and 154 patients with Novacor. All-time posttransplant hospitalizations due to 
rejection were similar between HeartMate and Novacor recipients after adjusting for patient 
case mix. Interestingly, although the PRA was higher in the HeartMate than the Novacor, 
this did not reach statistical difference. 
While there have been several attempts in reducing PRA levels prior to transplantation, 
none have shown consistent benefit in reducing absolute rejection episodes post 
transplantation. Even when leukofiltration has been shown to in reducing sensitization, 
there is no consistent evidence that it would reduce the burden of acute rejection. Further 
plasmapheresis can reduce the antibody burden, however the process and hospital-
dependent protocols in which it has been developed varies from one to the other. This 
variation of practice and protocols provides some uncertainty as to what is the best method 
for managing allosensitization. 
4. Infections and infection-related complications following heart VAD support 
in heart transplant recipients.  
Infection is one of the leading causes of mortality during ventricular assist device (VAD) 
observed during the randomized evaluation of mechanical assistance in chronic heart 
failure (i.e., REMATCH) Trial (Rose 2001). While the REMATCH was not directed towards 
heart transplantation, its findings are relevant. Bloodstream infection (BSI)  during VAD 
support is a unique clinical problem whose management is one of three options 1) local 
remedy of the infected VAD directly affecting the pocket or infected VAD valves 2) explant 
the VAD 3) replace the VAD  4)  cardiac transplantation. In a sub-set of patients with VADs, 
the BSI clears after appropriately treating the source. In others, the BSI persists without an 
identifiable extra-device source, strongly implicating device-related infection. A 
conservative approach to these patients, using long-term suppressive antibiotics, leads to 
40% to 50% mortality. Further, two reports have demonstrated infection rate of 50% after 
heart transplants in patients who had a LVAD. The reasons for this increased infection rate 
was likely due to many factors including the presence of foreign objects in the blood 
circulation, in addition to patient comorbidities and immune suppression (Omoto, Messner) 
In a study by the Pittsburgh group VAD patients who underwent heart transplantation from 
1987 to 2001 and who had BSI during VAD support, and who had positive cultures at VAD 
explant (device-related BSI, n = 10) were compared with those with negative cultures at 
explant (non–device-related BSI, n = 11) (Poston). Of the 123 patients who underwent VAD 
implantation at the University of Pittsburgh Medical Center from 1987 to 2001, a total of 65 
(53%) remained free of infection for the entire duration of support. The length of time that 
patients received VAD support was nearly 3 times longer in those with infection compared 
with those with no infection during VAD support (132 vs 48 days, p < 0.0001). The variables 
that were significant predictors of infection in univariate analysis (age, BMI, length of 
hospitalization pre- and post-VAD implantation, length of ICU stay, and history of alcohol 
abuse) all lost their significance when controlling for the length of VAD support. Only 
young age showed a trend for predicting infection (p = 0.06). Of the patients with devices 
who underwent heart transplantation during this time (88/123), infection of any type 
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(i.e., BSI or non-BSI) during VAD support was associated with significantly decreased 
survival after heart transplantation (p = 0.01). In the multivariate analysis, the only 
significant predictors of post-transplant mortality were any infection during device support 
(p < 0.01) and device-related BSI (p < 0.02).  
In this study, device-related BSI was a significant risk factor for pre-transplant mortality and 
showed a strong trend for adverse effects on post-transplant survival. Compared with those 
with no previous history of VAD support, 1-year post-transplant mortality in those with a 
history of device-related BSI nearly tripled (10% to 26%). After transplantation, these 
patients had significantly longer intubation requirements and worse renal function. 
Combined with heightened concerns of sepsis, a greater forced reduction in nephrotoxic 
immunosuppression was seen in those with former device-related BSI.  Some of the 
limitations in this study, were that inability to prospectively differentiate BSI as originating 
from a device vs a non-device source. A history of re-operation after initial VAD 
implantation and of prolonged ICU stay were also significant predictors in multivariate 
analysis that highlight the need for meticulous attention to hemostasis and the broad benefit 
of aprotinin. The latter unfortunately no longer exists given its side effects.  
Further in a similar study publishd in the Journal of Cardiac Surgery, we reviewed 1255 
patients with HeartMate I and 154 patients with Novacor. All-time posttransplant 
hospitalizations due to infection were similar between HeartMate and Novacor recipients 
after adjusting for patient case mix (Shuhaiber 2008). 
Overall, while infections have decreased in general due to several quality improvement 
initiatives both during surgery as well as postoperatively, an episode of infection during 
VAD can have direct implications on the post-transplant patient. Our group documented a 
case of pseudoaneurysm of the ascending aorta in a patient who had biventricular assist 
device for refractory ventricular fibrillation. Aortic aneurysms after heart transplantation are 
rare. Although this condition is associated with a history of infection, causality remains to be 
fully explained. The marked difference in compliance between donor and recipient aorta has 
been presented as a potential mechanism of pseudoaneurysm formation. However, other 
causes, such as suture dehiscence or aortic wall tissue necrosis, cannot be excluded. 
Resection of residual aortic tissue harboring pathogenic organisms associated with the aortic 
cannulation site of the VAD should be considered to avoid future aortic complications in 
this immunosuppressed group (Shuhaiber 2008). 
5. Neurocognitive following following VAD insertion 
With more than 5 million people sustaining heart failure and more than 550000 newly 
diagnosed each year. The number of VAD placements will only increase. While this occurs, 
there has been more interest in understanding quality of life for VAD patiens. One aspect 
regarding this involves neurocognitive changes (NC) in heart failure patients receiving left 
ventricular assist devices. While concerns have been raised about functional and 
nuerobehavioural changes during mechanical support, there are few studies objectively 
assessing this.  
One interesting study details neurocognitive function in heart failure patients receiving left 
ventricular assist devices. While the study did not review NC outcomes following heart 
transplantation, the findings are relevant in this review. A protocol designed to evaluate 
patient performance at 1, 3, 6 months after LVAD implantation at 11 centers was carried out. 
www.intechopen.com
 Ventricular Assist Devices 
 
210 
A total of 239 sessions were complete in 93 patients including paired evaluations in 51 to 57 
patients from 1 to 3 months, and in 20 to 28 patients with results from 1,3 and 6 months. Five 
NC domains were assessed, including visual spatial perception, auditory and visual 
memory, executive functions, language and processing speed. The devices included 
continuous-flow HeartMate II LVAD as a bridge to transplant. 
Overall there were no statistical significant differences but limited improvements between 
1,3 and 6 months in NC domain performances as seen in visual memory, executive functions 
and visual spatial perception and processing speed. Interestingly, there were no significant 
declines in any neurocognitive test in any domain over these time periods.    
The cognitive performance of advanced heart failure patients remained stable or showed 
slight improvments from month 1 to Month 6 of continuous-blood flow support with the 
HeartMate II LVAD. 
Patients who received a VAD and survived heart transplantation will have a recollection of 
the events surrounding both the time to VAD implantation, explantation and heart 
transplantation.  Such recollections can have an effect on their cognition, psychological 
feelings and thoughts. There has been much interest in the role of psychology, as well as 
behavioural responses following cardiac surgery in the adult population. For example, a 
proportion of patients with depression following heart surgery are associated with poor 
outcomes.  Patients following transplantation particularly with prior VAD implantation 
may have different psychological profile that is different from those with heart 
transplanation only. Further studies in understanding these differences may help in 
changing the outlook of such patients. 
Finally, when a VAD is implanted, there is subclinical thromboemboli formed systemically. 
This may surface clinically with direct injury to vital organs. The burden of thromboembolic 
disease can present with worsening end-organ function following heart transplantation. For 
example, if the kidney injury fails later, renal failure ensues and the survival of heart 
transplant recipient decreases. Or if there are unwitnessed decline in mental status from 
silent thromboemboli to the brain, neurocognitive impairment ensues. To provide some 
more quantitative numbers regarding thromboemboli complications following VAD, we 
reviewed autopsy findings of patients who had a temporary mechanical device placed 
(Levitronix).  Although we clinically witnessed 3 patients with cerebrovascular infarcts, 
autopsy revealed far more thromboembolic events (Shuhaiber 2009). Among the 18 patients 
who did not survive after Levitronix implantation, autopsy was obtained in 11 and the 
results show that 6 (54%) had evidence of thromboembolism, including pulmonary 
thromboembolism, and 3 had cerebrovascular infarcts. The autopsy findings of the non-
survivors demonstrated a bedside underestimation of the thromboembolic burden of VADs. 
The underlying etiology for thromboembolism was complex and related to cerebrovascular 
disease, calcification of the aorta, repeat operative procedures, recent myocardial infarction 
and mural thrombosis, as well as terminal low flow states with secondary venous and 
arterial thrombosis. Furthermore, 2 patients developed retroperitoneal hemorrhage  
from unknown causes contributing to significant blood loss, which were not clinically 
apparent. 
The next decade will begin to appreciate these intricate areas further as the methods of 
diagnosis and assessment of bleeding as well thromboembolic disease during VAD support 
become more sophisticated and reliable.  
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6. Future directions and follow up of patients following VAD bridged to heart 
transplantation  
The future has been rewarding since the introduction of VADs into surgery. Its role in 
prolonging the lives of patients who would not otherwise be candidates or live long enough 
for heart transplantation has been astounding. The current state of affairs in VAD 
technology is continuous evolution of myriad of devices for various diagnostic 
cardiomyopathy patients. Quality outcome research and assessment of small series for 
different patient cohortsdifferent patient cohort is not the best way to study the device at 
hand especially since not all patients survive VAD implantation and or heart 
transplantation. Standardized clinical assessment and management protocols for designated 
safe VAD in qualified institutions is essential before we can fully appreciate the impact of 
VAD on post heart transplant outcomes. While certain devices may suit some patients, 
others may not benefit from this. The next challenge is to begin stratifying those patients 
who will benefit them the most. 
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